bioAffinity Technologies releases case study showing CyPath Lung helps avoid biopsy in elderly patient

bioAffinity Technologies, Inc.

CyPath Lung test was negative for a 79-year-old woman with suspicious LDCT finding, supporting surveillance over invasive biopsy.
Repeat CT scan in October 2025 showed nodule resolved, validating the conservative management decision.
Test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in nodules <2 cm.
Case study highlights CyPath Lung's role in reducing unnecessary procedures in high-risk patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.